NEW YORK (GenomeWeb) – Fitch Ratings today affirmed Quest Diagnostics' ratings at BBB with a stable ratings outlook. 

The rating action applies to about $3.86 billion of debt. 

Fitch noted Quest's leading position in a fragmented and competitive US clinical laboratory market, saying its scale "affords the opportunity for comparatively efficient operations and supplies sourcing, and the ability to drive associated margin improvement following" merger and acquisition deals. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.